1. BAILLIE GIFFORD CHINA GROWTH TRUST
    BAILLIE GIFFORD CHINA GROWTH TRUST

    Overview

    Baillie Gifford China Growth Trust aims to produce long term capital growth by investing predominantly in shares of, or depositary receipts representing the shares of, Chinese companies.

    Performance & Portfolio

    Periodic Performance

    The value of your investment may go down as well as up, and you may not get back the amount you invested.
    NAV is calculated with borrowings deducted at fair value for 1, 3 and 5 years and par value for 10 years.
    *Changed from MSCI AC Asia ex Pacific index to MSCI China All Shares Index on 16/09/20. Data chain-linked from this date to form a single comparative index
    Performance source: Morningstar and relevant underlying index provider, total return.
    Please bear in mind that past performance is not a guide to future performance.


    Discrete Performance

    The value of your investment may go down as well as up, and you may not get back the amount you invested.
    NAV is calculated with borrowings deducted at fair value for 1, 3 and 5 years and par value for 10 years.
    *Changed from MSCI AC Asia ex Pacific index to MSCI China All Shares Index on 16/09/20. Data chain-linked from this date to form a single comparative index
    Performance source: Morningstar and relevant underlying index provider, total return.
    Please bear in mind that past performance is not a guide to future performance.

    Holdings - 31/03/2021

    Fund %
    1 Tencent 9.9%
    2 Alibaba 9.1%
    3 Ping An Insurance 4.5%
    4 ByteDance 4.3%
    5 Meituan Dianping 4.0%
    6 Kweichow Moutai 3.4%
    7 China Merchants Bank 2.7%
    8 Bilibili 2.6%
    9 Zai Lab 2.3%
    10 Li Ning 2.1%
    Total 45.0%
    All holdings of 0.7% and above
    Fund %
    1 Tencent 9.9%
    2 Alibaba 9.1%
    3 Ping An Insurance 4.5%
    4 ByteDance 4.3%
    5 Meituan Dianping 4.0%
    6 Kweichow Moutai 3.4%
    7 China Merchants Bank 2.7%
    8 Bilibili 2.6%
    9 Zai Lab 2.3%
    10 Li Ning 2.1%
    11 CATL 2.1%
    12 JD.com 2.1%
    13 Ping An Bank 2.0%
    14 Guangzhou Kingmed Diagnostics Group 1.8%
    15 BeiGene 1.7%
    16 WuXi AppTec 1.6%
    17 NetEase 1.6%
    18 Midea 1.5%
    19 China Molybdenum 1.5%
    20 Shenzhou International 1.4%
    21 Geely Automobile 1.3%
    22 Hangzhou Tigermed Consulting 1.3%
    23 Weichai Power 1.3%
    24 Asymchem Laboratories 1.2%
    25 Kingsoft 1.2%
    26 Sunny Optical Technology 1.2%
    27 KE Holdings 1.2%
    28 ENN Energy 1.1%
    29 Burning Rock Biotech 1.1%
    30 Kingdee International Software 1.1%
    31 Huayu Auto Systems 1.1%
    32 Brilliance China Automotive 1.1%
    33 Fuyao Glass Industry 1.1%
    34 Shenzhen Megmeet Electrical 1.1%
    35 Luzhou Lao Jiao Company 1.1%
    36 Lufax Holding 1.1%
    37 Shenzhen Inovance Technology 1.0%
    38 Zhejiang Sanhua Intelligent Controls 1.0%
    39 Jiangsu Hengrui Medicine 1.0%
    40 Tencent Music Entertainment Group 1.0%
    41 Topchoice Medical Investment 1.0%
    42 Dada Nexus 1.0%
    43 Estun Automation 1.0%
    44 Pop Mart International 0.9%
    45 Glodon Company 0.9%
    46 PROYA Cosmetics 0.9%
    47 Yatsen Holding Limited 0.8%
    48 Yonyou 0.8%
    Total 92.1%

    Meet the Managers

    Sophie Earnshaw

    Sophie joined Baillie Gifford in 2010 and is an Investment Manager in the Emerging Markets and China A-share Teams. She has also been Co-Manager of the China Fund and a member of the International Focus Portfolio Construction Group since 2014. Sophie is a CFA Charter holder. She graduated MA in English Literature from the University of Edinburgh in 2008 and MPhil in Eighteenth Century and Romantic Literature from the University of Cambridge in 2009.

    Roderick Snell

    Roderick joined Baillie Gifford in 2006 and is an Investment Manager in the Emerging Markets Equity Team. He has co-managed the Baillie Gifford Pacific Fund since 2010 and has been Deputy Manager of Pacific Horizon Investment Trust since 2013. Since March 2020, he has also been a co-manager of the Baillie Gifford China Fund. He spent time in the UK and European Equity teams prior to joining the Emerging Markets Equity Team in 2008. Roderick graduated BSc (Hons) in Medical Biology from the University of Edinburgh in 2006.

    Documents

    You can access any literature about the Fund here, either by downloading or requesting a copy by post (where available). Please note that, due to current government restrictions, we have a limited number of staff in our office. As a result, if posting instructions to us, there may be a delay in processing these due to these current restrictions.

    To download any document you will need Adobe Reader. Please note that we can now provide you with Braille and audio transcriptions of our literature on request. It may take up to 10 days for the transcription to be completed dependent on the size of the document.

    Bulletins and Factsheets

    Disclaimers

    MSCI Disclaimer

    Source: MSCI.  The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.  Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction.  The MSCI information is provided on an ‘as is’ basis and the user of this information assumes the entire risk of any use made of this information.  MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the ‘MSCI Parties’) expressly disclaims all warranties (including, without limitation, any warranties or originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information.  Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com)